| ★ |  Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | |
| 5 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 90 |
| 3 |  IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 90 |
| 12 |  ERN ReCONNET: the New 2026 Webinar Series | | 630 | — | 88 |
| 4 |  Recent advances in the treatment of inflammatory myopathies | | 618 | — | 90 |
| 13 |  CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 88 |
| 10 |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | 89 |
| 17 |  Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 88 |
| 15 |  Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 88 |
| 20 |  Microvascular Involvement in Antiphospholipid Syndrome (APS) | | 264 | — | 88 |
| 1 |  Systemic sclerosis and pregnancy, a 2026 update | | 257 | — | 91 |
| 18 |  Pulmonary Function Tests: A Practical Guide for Rheumatologists | | 253 | — | 88 |
| 14 |  Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 88 |
| 19 |  The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 88 |
| 8 |  ERN ReCONNET New Sjögren’s Syndrome (SS) Disease Coordinator: Prof. Gaetane Nocturne (EN) | | 133 | — | 89 |
| 7 |  Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 89 |
| 9 |  ERN ReCONNET New Sjögren’s Syndrome (SS) Disease Coordinator: Prof. Gaetane Nocturne (FR) | | 99 | — | 89 |
| 16 |  3rd ERN ReCONNET Sharing Good Practice 2025 Event | | 84 | — | 88 |
| 6 |  Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 89 |
| 2 |  Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 91 |
| 11 |  Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 89 |